Saxenda Month-by-Month: What Really Happens in the First 3 Months

What the first 3 months actually contain

Saxenda is liraglutide 3 mg, a once-daily GLP-1 receptor agonist for weight management, injected subcutaneously in the abdomen, thigh, or upper arm at any time of day, without regard to meals [1]. The label's schedule is 0.6 mg daily for week 1, then 1.2 mg, 1.8 mg, and 2.4 mg in weekly steps, reaching 3 mg daily from week 5 [1]. Lower doses are for titration only; the recommended adult dose is 3 mg daily, and the label says to discontinue in adults if 3 mg is not tolerated [1]. Only the pediatric instructions allow a drop to 2.4 mg daily [1]. Month 3 leads up to the week-16 check.

Month 1: The ramp and GI effects

Month 1 covers weeks 1 to 4 and doses 0.6 mg to 2.4 mg. The adult trial rates below cover the whole treatment period, not month 1 alone. In 5 placebo-controlled trials (3,384 on Saxenda, 1,941 on placebo, up to 56 weeks at 3 mg daily), nausea occurred in 39.3% vs 13.8%, diarrhea 20.9% vs 9.9%, constipation 19.4% vs 8.5%, and vomiting 15.7% vs 3.9% [1]. About 68% vs 39% reported any GI disorder, and nausea declined as treatment continued [1]. Discontinuation for adverse reactions was 9.8% vs 4.3% [1].

Month 2: First weeks at 3 mg

Week 5 is the first week at 3 mg. The label says to monitor heart rate at regular intervals [1]. Mean resting heart rate rose 2 to 3 bpm; rises above 10 bpm at two consecutive visits occurred in 34% vs 19%, and at least one resting rate above 100 bpm in 6% vs 4% [1]. The label also lists acute pancreatitis, acute gallbladder disease, and acute kidney injury from volume depletion among warnings [1]. Cholelithiasis was reported in 2.2% vs 0.8% and cholecystitis in 0.8% vs 0.4% [1].

Month 3: Approaching the week-16 checkpoint

The formal check is week 16 and the 4% threshold [1]. The 56-week SCALE Obesity and Prediabetes trial is the anchor: 3,731 adults without type 2 diabetes, BMI at least 30 or at least 27 with dyslipidemia or hypertension, randomized to liraglutide 3 mg (n=2,487) or placebo (n=1,244) plus lifestyle counseling [2]. Mean weight loss was 8.4 kg with Saxenda versus 2.8 kg with placebo, and 63.2% versus 27.1% lost at least 5% of body weight [2]. Those are 56-week results, not month-3 results.

Safety points that matter early

The boxed warning covers thyroid C-cell tumors in rats and mice; human relevance is unknown, and Saxenda is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. The label says to discontinue if pancreatitis is suspected and says Saxenda is not recommended in severe gastroparesis [1]. Hypoglycemia risk rises with insulin or a sulfonylurea, and the label says the risk may be lowered by reducing that dose [1].